Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Previous studies indicate amygdala activity (AmygA) measured by FDG-positron emission tomography (PET) predicts the risk of subsequent cardiovascular events. However, AmygA measurement use for predicting the prognosis of patients with cardiac sarcoidosis (CS) is unknown. We aimed to investigate the association between AmygA and cardiovascular events in patients with CS. METHODS: Consecutive 40 patients with CS who underwent FDG-PET were identified retrospectively. Cardiovascular events included ventricular tachyarrhythmias and heart failure hospitalizations. We examined the association between AmygA and cardiovascular events and investigated the timing of FDG-PET influence on AmygA measurements. RESULTS: During a follow-up of 4.5 (2.5-7.7) years, 14 (35%) patients experienced cardiovascular events. Left-AmygA was a stronger cardiovascular event predictor than the Right-AmygA, and incidences were significantly higher in the high left-AmygA group than low group (log-rank P = 0.018). Multivariable analysis revealed left-AmygA augmentation (hazard ratio [HR]: 1.76 per 0.1 increase, 95% confidence interval [CI]: 1.12-2.87, P = 0.016) was the only independent predictor of cardiovascular event. Among the 40 patients, 32 underwent multiple PET-scans. No significant difference was found between the AmygA value on the first PET-scan and the mean on multiple PET scans, and the correlation coefficient was 0.93 (P < 0.001). Multivariate analyses revealed the mean left-AmygA value was the only independent predictor of cardiovascular event (P = 0.011). CONCLUSIONS: High left-AmygA was associated with the higher rates of cardiovascular events in patients with CS. AmygA would be a prognostic biomarker regardless of the PET-scan timing.

DOI： 10.1007/s00259-025-07266-3

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s00259-024-07030-z

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: In chronic kidney disease (CKD) cardiovascular remodeling (CVR) is very frequent compared with general population and, as suppose, may be associated with «new» renal risk factors. The aim of study was to estimate association of new serum biomarkers (FGF-23, Klotho) and traditional biomarker of cardiac damage-serum Troponin I (sTr-I) with signs of CVR. METHODS: One hundred thirty CKD G1-5D patients without cardiovascular disease (CVD) clinical manifestation were included. We measured serum FGF-23, Klotho and sTr-I. The instrumental methods were: echocardiography, SphygmoCor test [Pulse Wave Velocity (PWV), Central (aortic) Blood Pressure (CBP), Subendocardial Blood Supply (SBS)]. RESULTS: FGF-23 level correlated with: sTr-I (r = 0.512; p < 0.01), eccentric left ventricular hypertrophy, LVH (r = 0.543; p < 0.01), SBS (r = - 0.499; p < 0.05). There were no differences of FGF-23 level in patients with normal and high CBP. Klotho correlated with concentric LVH (r = - 0.451; p < 0.01), PWV (r = - 0.667; p < 0.001), Cardiac Calcification Score, CCS (r = - 0.581; p < 0.01). Multivariate analysis revealed positive independent association of FGF-23 with eccentric LVH (OR = 1.036, 95% CI (1.004-1.068); p = 0.038). Klotho was a negative determinant for concentric LVH (OR = 0.990, 95% CI 0.987-0.994; p < 0.001), increased PWV (OR = 0.984, 95% CI (0.977-0.991); p < 0.001) and CCS (OR = 0.991, 95% CI (0.988-0.995); p < 0.001). In addition, multivariate analysis revealed a relationship between serum Klotho (OR = 0.980, 95% CI (0.964-0.996); p = 0.016), FGF-23 (OR = 3.145, 95% CI (1.020-9.695); p = 0.046) and troponin I level. CONCLUSION: In CKD patients without CVD clinical manifestation increased serum FGF-23 level and decreased Klotho are associated with CVR: FGF-23 with eccentric LVH (independently of CBP), Klotho determinate concentric LVH, PWV and CCS. Moderately elevated sTr-I levels may be a manifestation of FGF-23/Klotho imbalance in CKD.

DOI： 10.1007/s11255-021-03046-8

PubMed

researchmap

Language：English  

DOI： 10.1007/s00415-021-10650-2

PubMed

researchmap

Language：Russian   Publishing type：Research paper (scientific journal)   Publisher：Scientific Center of Neurology  

В диагностике эпилепсии важное место отводится описанию симптомов эпилептических приступов иктальной семиологии. Иктальные симптомы, или знаки, главным образом подразделяются на локализационные и латерализационные. Среди последних отдельное место занимают знаки, указывающие на реализацию приступов доминантным или субдоминантным полушарием. Проведен анализ работ, в которых исследовалась латерализационная значимость тех или иных иктальных знаков в контексте доминантности полушарий. В данном обзоре описаны такие симптомы эпилептических приступов, как питье воды, улыбка, нарушение речи и другие, опираясь преимущественно на исследования, в которых локализация эпилептогенной зоны доказывалась ремиссией после резективной операции. Несмотря на недостаточную статистическую значимость отдельных латерализационных знаков, сочетание нескольких знаков, говорящих в пользу одного и того же полушария, позволяет повысить точность определения эпилептогенной зоны, что у пациентов с фармакорезистентной эпилепсией может улучшить исход последующего хирургического лечения.

ctal semiology describes signs and symptoms of epileptic seizures, also known as ictal signs. Most commonly, ictal signs are divided into localizing and lateralizing ones. Among the latter, signs lateralizing to dominant or nondominant hemisphere are of remarkable interest. We analyzed the studies on the lateralizing value of various ictal signs in regard to hemisphere dominance. This review covers periictal water drinking, smile, speech disturbances and other ictal signs. Studies with seizure freedom as a result of resective surgery were of higher priority. Even though particular ictal signs may have insufficient statistical significance, their combinations might improve the accuracy of epileptogenic zone identification, which is crucial for surgical treatment of drugresistant epilepsy.

DOI： 10.25692/asy.2019.13.4.011

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：Russian   Presentation type：Oral presentation (invited, special)  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

researchmap